Data Year:

For its 2025 fiscal year, VANDA PHARMACEUTICALS INC, listed the following executives on its annual proxy statement to the SEC

Equity
Cash Compensation
Other
Fiscal Year Ended in 2025
Name And Title Total Compensation Pay Rank By Title In Biotechnology industry
Mihael H. Polymeropoulos M.D.
President, Chief Executive Officer and Chairman of the Board
Total Compensation $3,851,468 View details Pay Rank By Title In Biotechnology industry #303 View more
Gunther Birznieks
Senior Vice President, Business Development
Total Compensation $1,415,471 View details Pay Rank By Title In Biotechnology industry #13 View more
Timothy Williams
Senior Vice President, General Counsel and Secretary
Total Compensation $1,444,969 View details Pay Rank By Title In Biotechnology industry #64 View more
Kevin Moran
Senior Vice President, Chief Financial Officer and Treasurer
Total Compensation $1,439,660 View details Pay Rank By Title In Biotechnology industry #303 View more
Joakim Wijkstrom
Senior Vice President, Chief Marketing Officer
Total Compensation $1,457,528 View details Pay Rank By Title In Biotechnology industry #3 View more

The charts on this page feature a breakdown of the total annual pay for the top executives at VANDA PHARMACEUTICALS INC as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. VANDA PHARMACEUTICALS INC income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. VANDA PHARMACEUTICALS INC annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
Mihael H. Polymeropoulos M.D.
President, Chief Executive Officer and Chairman of the Board
Total Cash $1,799,981 Equity $2,007,000 Other $44,487 $3,851,468
Gunther Birznieks
Senior Vice President, Business Development
Total Cash $832,064 Equity $557,500 Other $25,907 $1,415,471
Timothy Williams
Senior Vice President, General Counsel and Secretary
Total Cash $832,064 Equity $557,500 Other $55,405 $1,444,969
Kevin Moran
Senior Vice President, Chief Financial Officer and Treasurer
Total Cash $832,064 Equity $557,500 Other $50,096 $1,439,660
Joakim Wijkstrom
Senior Vice President, Chief Marketing Officer
Total Cash $861,286 Equity $557,500 Other $38,742 $1,457,528
For its 2025 fiscal year, VANDA PHARMACEUTICALS INC, listed the following CEO pay ratio data on its annual proxy statement to the SEC.
CEO Name CEO Pay Median Employee Pay CEO Pay Ratio
Mihael H. Polymeropoulos M.D. CEO Pay $3,851,468 Median Employee Pay $166,623 CEO Pay Ratio 23:1
For its 2024 fiscal year, VANDA PHARMACEUTICALS INC, listed the following board members on its annual proxy statement to the SEC.
Name Total COMPENSATION
Anne Sempowski Ward Total Cash $306,864
Phaedra S. Chrousos Total Cash $302,908
Richard W. Dugan Total Cash $336,864
Stephen Ray Mitchell Total Cash $282,496
Tage Honoré Total Cash $285,033
Browse Board of Directors By First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Executives by First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Companies by Company Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

Use of Data / Disclaimer

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

What is a proxy statement?

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.